InMed Pharmaceuticals (INM) Enterprise Value (2021 - 2025)
InMed Pharmaceuticals (INM) has 5 years of Enterprise Value data on record, last reported at -$7.0 million in Q4 2025.
- For Q4 2025, Enterprise Value fell 25.23% year-over-year to -$7.0 million; the TTM value through Dec 2025 reached -$7.0 million, down 25.23%, while the annual FY2025 figure was -$11.1 million, 68.1% down from the prior year.
- Enterprise Value reached -$7.0 million in Q4 2025 per INM's latest filing, up from -$9.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$1.1 million in Q1 2024 and bottomed at -$15.4 million in Q3 2021.
- Average Enterprise Value over 5 years is -$7.6 million, with a median of -$6.9 million recorded in 2023.
- Peak YoY movement for Enterprise Value: skyrocketed 88.96% in 2024, then plummeted 343.04% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$11.3 million in 2021, then dropped by 1.5% to -$11.5 million in 2022, then skyrocketed by 88.23% to -$1.4 million in 2023, then tumbled by 315.82% to -$5.6 million in 2024, then dropped by 25.23% to -$7.0 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$7.0 million in Q4 2025, -$9.4 million in Q3 2025, and -$11.1 million in Q2 2025.